Ontario Budget 2017: Innovative Medicines Canada commends the Ontario government on improving drug access

Posted on April 27, 2017

Toronto, April 27, 2017 – In response to the budget tabled by Ontario Finance Minister Charles Sousa, Innovative Medicines Canada welcomes the Government of Ontario’s initiative to launch OHIP+, a program that will cover the cost of prescription medications for every Ontarian under the age of 24, starting next January.

“Innovative Medicines Canada congratulates the Government of Ontario on this bold step forward as it represents an important milestone for access to drugs in the province,” said Pamela Fralick, President of Innovative Medicines Canada. “Innovative medicines play an important role in patients’ health and we are pleased to see that all of Ontario’s youth will benefit from this plan.”

As the province moves forward with OHIP+, Innovative Medicines Canada is eager to work with the government. We support a program that will have the best standard of care, and support a health care system that achieves the best outcomes for patients by providing access to a full range of medicines to meet diverse patient needs.

“We are committed to working with the Government of Ontario to further improve access to medicines for Ontarians as well as provide predictability for the government and manufacturers,” added Ms. Fralick.

Innovative Medicines Canada is also encouraged to note the $11.5 billion investment by the Government of Ontario over the next three years to support key pillars such as access to care, expanded mental health and addiction services including funding to improve wait times.

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

– 30 –

For further information:

Sarah Dion-Marquis
Media Relations

Leave a Reply

Your email address will not be published. Required fields are marked *